Research Reference
CJC-1295 DAC
Long-acting GHRH analog — 8-day half-life, weekly dosing
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
CJC-1295 DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that covalently binds to serum albumin, extending its half-life to approximately 8 days. It is the only GHRH analog with human clinical trial data demonstrating dose-dependent, prolonged GH and IGF-1 elevation.
Community dosing is not based on clinical trial goals. The key advantage is weekly or twice-weekly dosing vs 2–3 daily injections for the no-DAC version — significantly better adherence.
Standard community protocol: 2 mg twice weekly, 12–16 weeks on/off.
Side Effects & Safety
- Injection site reactions — most common in clinical trials (mild erythema, pain)
- Flushing/warmth — transient, 15–30 min post-injection
- Water retention — more pronounced than no-DAC due to sustained GH elevation
- Numbness/tingling — carpal tunnel-like symptoms at higher doses
- Joint stiffness — GH-mediated fluid retention
- Insulin resistance — monitor fasting glucose; sustained GH can impair glucose tolerance
- No serious adverse events reported in published clinical trials
- Contraindications — active malignancy, diabetic retinopathy, pregnancy
Monitoring (community protocols): Monitor IGF-1 at baseline, week 4, and every 8 weeks, targeting 250–330 ng/mL. Fasting glucose is commonly tracked monthly; HbA1c at 3-month intervals when insulin resistance is a concern.
Research Basis
CJC-1295 DAC is unique among GH secretagogues in having direct human clinical trial data.
Pivotal study (Teichman et al., 2006): Studied CJC-1295 DAC in 36 healthy adults (21–61 years). Single doses of 30, 60, or 120 mcg/kg produced dose-dependent GH and IGF-1 increases. IGF-1 increased 1.5–3 fold and remained elevated for 6–14 days. Mean half-life: 5.8–8.1 days.
Preserved pulsatility (Ionescu & Bhatt, 2006): Despite continuous GHRH stimulation, pulsatile GH secretion was maintained. GH pulse frequency preserved with 2-fold increases in mean GH and pulse mass.
Animal studies (Alba et al., 2006): CJC-1295 normalized growth in GHRH knockout mice with once-daily dosing.
Community doses (1–4 mg twice weekly) target upper-normal IGF-1 based on clinical dose ranges and empirical blood work confirmation.